AR129012A1 - Derivados de piridazina fusionados - Google Patents
Derivados de piridazina fusionadosInfo
- Publication number
- AR129012A1 AR129012A1 ARP230100862A ARP230100862A AR129012A1 AR 129012 A1 AR129012 A1 AR 129012A1 AR P230100862 A ARP230100862 A AR P230100862A AR P230100862 A ARP230100862 A AR P230100862A AR 129012 A1 AR129012 A1 AR 129012A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyridazine derivatives
- fused pyridazine
- formula
- compounds
- fused
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263328709P | 2022-04-07 | 2022-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129012A1 true AR129012A1 (es) | 2024-07-03 |
Family
ID=86329425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100862A AR129012A1 (es) | 2022-04-07 | 2023-04-05 | Derivados de piridazina fusionados |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250340563A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4504733A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025511819A (cg-RX-API-DMAC7.html) |
| AR (1) | AR129012A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202345838A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023194964A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CA3226995A1 (en) * | 2021-07-21 | 2023-01-26 | Nico Therapeutics, Inc. | Annulated pyridazine compound |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3及glp-1a組合療法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| AR119731A1 (es) * | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| TW202231281A (zh) * | 2020-12-25 | 2022-08-16 | 大陸商上海拓界生物醫藥科技有限公司 | 一類含噠嗪的化合物及其醫藥用途 |
| CA3226995A1 (en) * | 2021-07-21 | 2023-01-26 | Nico Therapeutics, Inc. | Annulated pyridazine compound |
-
2023
- 2023-04-05 AR ARP230100862A patent/AR129012A1/es unknown
- 2023-04-07 TW TW112113100A patent/TW202345838A/zh unknown
- 2023-04-07 WO PCT/IB2023/053561 patent/WO2023194964A1/en not_active Ceased
- 2023-04-07 EP EP23722044.7A patent/EP4504733A1/en active Pending
- 2023-04-07 JP JP2024559337A patent/JP2025511819A/ja active Pending
- 2023-04-07 US US18/854,298 patent/US20250340563A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025511819A (ja) | 2025-04-16 |
| TW202345838A (zh) | 2023-12-01 |
| EP4504733A1 (en) | 2025-02-12 |
| WO2023194964A1 (en) | 2023-10-12 |
| US20250340563A1 (en) | 2025-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022004684A2 (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
| MX2021013135A (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2. | |
| DOP2024000275A (es) | Compuestos de pirido[4,3-d]pirimidina | |
| AR127050A1 (es) | Compuestos espirocíclicos | |
| AR119910A1 (es) | DERIVADOS DE 4,4a,5,7,8,8a-HEXAHIDROPIRIDO[4,3-b][1,4]OXAZIN-3-ONA COMO INHIBIDORES DE MAGL | |
| AR123018A1 (es) | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este | |
| AR030959A1 (es) | Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen | |
| AR114421A1 (es) | Piperidinil-3-(ariloxi)-propanamidas y propanoatos | |
| AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
| CL2022003067A1 (es) | Derivados de n-(piperidin-4-il)benzamida de acción luminal | |
| ECSP22082217A (es) | Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida | |
| AR036094A1 (es) | Compuestos derivados de acido sulfonico, composicion farmaceutica y su uso en la preparacion de medicamentos | |
| CL2025002805A1 (es) | Derivados de amida para inhibir nlrp3 y usos de estos. | |
| CL2025000529A1 (es) | Compuestos derivados de dioxoisoquinolinona, inhibidores de ezh1 y/o ezh2; uso para tratar cáncer. | |
| AR131705A1 (es) | Derivados de 1-amino-4-fenilftalazina | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| AR123977A1 (es) | 1h-pirazolo[4,3-c]piridinas sustituidas y derivados como inhibidores de egfr | |
| CO2024017138A2 (es) | Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas | |
| CL2024002101A1 (es) | Proceso de elaboración de derivados de morfolinas sustituidas | |
| DOP2025000013A (es) | Inhibidores de inflamasoma nlrp3 | |
| CO2025010159A2 (es) | Derivados de 3-(2-(dimetilamino)etil)-1h-indol-4-ilo | |
| AR125397A1 (es) | Modified ferroportin inhibitors | |
| AR129605A1 (es) | PÉPTIDOS CÍCLICOS PARA ATRAPAR INTERLEUCINA-1b | |
| CO2026004514A2 (es) | Derivados tricíclicos y usos relacionados | |
| AR132037A1 (es) | Derivados de piridazinil amino como inhibidores del receptor alk5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |